Cardiff Oncology Maintains Busy Investor Outreach Schedule

CEO Mark Erlander is scheduled to present today at the H.C. Wainwright Global Investment Conference, marking the company’s third major investor event this week. This appearance follows recent presentations at conferences hosted by Wells Fargo and Morgan Stanley, demonstrating a concerted effort to engage with the investment community.

The company maintains a solid financial foundation with approximately $71 million in cash and short-term investments. During the second quarter, the monthly cash burn rate averaged $8.3 million. Based on these figures, Cardiff Oncology’s current liquidity is projected to fund operations through the first quarter of 2027, providing substantial runway to advance its clinical development programs.

At the core of the company’s value proposition is Onvansertib, a PLK1 inhibitor that Read more...